- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02455804
NIRTRAKS Post-Market Study (NIRTRAKS) (NIRTRAKS)
October 3, 2023 updated by: Medinol Ltd.
NIRTRAKS - (NIRxcell TRial for a Post mArKet Study)
This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US).
All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure.
An unscheduled follow up may be conducted as clinically warranted.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The main objective of this study is to collect and analyze additional information about the safety and effectiveness of the NIRxcell Stent System in the treatment of de novo stenotic lesions in native coronary arteries in the US population.
The primary endpoint will be the rate of target vessel failure (TVF) at 3 years of treatment with the NIRxcell Stent System.
This rate will be compared with a performance goal derived from a meta-analysis of coronary stenting with bare metal stents (BMS).
Study Type
Interventional
Enrollment (Actual)
65
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Health System
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
General
- Subject is ≥18 years old.
- Subject is eligible for percutaneous coronary intervention (PCI).
- Subject is eligible for dual anti-platelet therapy (DAPT) with aspirin plus either clopidogrel, prasugrel or ticagrelor for a minimum of 1 month.
- Subject understands the nature of the procedure and provides written informed consent prior to the catheterization procedure.
- Subject is willing to comply with specified follow-up evaluation and can be contacted by telephone.
- Subject is an acceptable candidate for coronary artery bypass graft (CABG) surgery.
- Subject has stable angina pectoris (Canadian Cardiovascular Society Classification [CCSC] 1, 2, 3 or 4) or unstable angina pectoris (Braunwald Class 1-3, B-C) or a positive functional ischemia study (e.g. exercise tolerance test [ETT], single-photon emission computerized tomography [SPECT], stress echocardiography or cardiac computerized tomography [CT]).
- Female subjects of child bearing potential must have a negative pregnancy test within 7 days prior to enrollment in the study.
Angiographic Inclusion Criteria
- Subject is indicated for elective stenting of a single stenotic lesion in a native coronary artery.
- Reference vessel ≥2.5 mm and ≤4.0 mm in diameter by visual estimate.
- Target lesion ≤30 mm in length by visual estimate (the intention should be to cover the whole lesion with 1 stent of adequate length).
- Target lesion stenosis ≥50% and <100% by visual estimate.
Exclusion Criteria:
General Exclusion Criteria
- Subject is currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints.
- Subject was enrolled in another stent trial within 2 years prior to the index procedure.
- Any planned elective surgery or percutaneous intervention within 9 months post- procedure.
- A previous coronary interventional procedure of any kind within 30 days prior to the procedure.
- The subject requires staged procedure of either the target vessel or any non-target vessel within 9 months post-procedure.
- The target lesion requires treatment with a device other than percutaneous transluminal coronary angioplasty (PTCA) prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.).
- Previous drug-eluting stent (DES) deployment anywhere in the target vessel.
- Any previous DES deployment within the past 12 months.
- Any previous stent placement within 15 mm proximal or distal to the target lesion.
- Co-morbid condition(s) that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial.
- Concurrent medical condition with a life expectancy of <3 years.
- Documented left ventricular ejection fraction (LVEF) <25% at the most recent evaluation.
- Evidence of an acute MI within 72 hours of the intended index procedure.
- History of cerebrovascular accident or transient ischemic attack within 6 months prior to the index procedure.
- Leukopenia (leukocytes <3.5 x 109/liter).
- Neutropenia (absolute neutrophil count <1,000/mm3) ≤ within 7 days prior to enrollment.
- Thrombocytopenia (platelets <100,000/mm3) pre-procedure (within 7 days prior to enrollment).
- Active peptic ulcer or active gastrointestinal (GI) bleeding.
- Subjects who are ineligible for ≥1 month of DAPT because of bleeding diathesis or any other reason.
- Known hypersensitivity or contraindication to aspirin, thienopyridine, both heparin and bivalirudin, cobalt, nickel, L-605 cobalt chromium alloy or sensitivity to contrast media which cannot be adequately pre-medicated.
- Serum creatinine level >2.5 mg/dL within 7 days prior to the index procedure.
- Subject was previously enrolled in the PIONIR Study or the NIRTRAKS Post-Market Study.
Angiographic Exclusion Criteria
- Unprotected left main coronary artery disease (obstruction >50% in the left main coronary artery that is not protected by ≥1 non-obstructed bypass graft to the left anterior descending [LAD] or left circumflex [LCX] artery or a branch thereof).
- Target vessel exhibiting multiple lesions with >60% diameter stenosis outside of a range of 5 mm proximal and distal to the target lesion based on visual estimate or on-line quantitative coronary angiography (QCA).
- Target lesion exhibiting an intraluminal thrombus (occupying >50% of the true lumen diameter) at any time prior to the start of the intervention.
- Lesion location that is aorto-ostial or within 5 mm of the origin of the LAD or LCX.
- Target lesion with side branches >2.0 mm in diameter.
- Target lesion involving a bifurcation (either stenosis of both main vessel and major branch or stenosis of just major branch).
- Target lesion with severe calcification.
- Target vessel exhibiting excessive tortuosity that may impede stent delivery and deployment at target lesion.
- Target lesion that is located in a native vessel distal to an anastomosis with a saphenous vein graft or a left/right internal mammary artery (LIMA/RIMA) bypass.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single Arm
This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US).
All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure.
An unscheduled follow up may be conducted as clinically warranted.
|
All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure.
An unscheduled follow up may be conducted as clinically warranted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target Vessel Failure
Time Frame: 3 years
|
The primary endpoint in this study was TVF (Target Vessel Failure) defined as a composite of cardiac death, target vessel myocardial infarction (MI), or clinically driven target vessel revascularization (TVR) by percutaneous or surgical methods within 3 years post-procedure.
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Manesh R Patel, MD, FACC, Duke Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2016
Primary Completion (Actual)
January 14, 2020
Study Completion (Actual)
January 14, 2020
Study Registration Dates
First Submitted
May 26, 2015
First Submitted That Met QC Criteria
May 26, 2015
First Posted (Estimated)
May 28, 2015
Study Record Updates
Last Update Posted (Actual)
October 4, 2023
Last Update Submitted That Met QC Criteria
October 3, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- CV103-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on de Novo Stenotic Lesions in Native Coronary Arteries
-
Biotronik AGCompletedde Novo Lesions in Native Coronary ArteriesNetherlands, Switzerland, Germany, Belgium
-
Biosensors Europe SACompleted
-
Abbott Medical DevicesBaim Institute for Clinical ResearchWithdrawnWith de Novo or Restenotic Lesions in the Common and/or External Iliac Arteries
-
Tryton Medical, Inc.CompletedCoronary Atherosclerosis of Native Coronary Artery | Bifurcation Lesions: de Novo Lesions of the Main and Side Branch of Native Coronary ArteryUnited States
-
Biotronik AGCompletedDe Novo and Re-stenosed Coronary Artery LesionsSwitzerland, Netherlands, Israel, Spain, Latvia, Germany, Austria, Belgium, France, Ireland
-
Tel-Aviv Sourasky Medical CenterCompletedConsecutive Subjects Who Are Suitable for a Coronary | Angioplasty of de Novo Lesion(s) in Native Coronary | Arteries Should be Screened for Eligibility. | A Total Number of 200 Patients Fulfilling the Selection | Criteria and Willing to Sign the Informed Consent Should | be Enrolled in the...Israel
-
Boston Scientific CorporationCompletedCardiovascular Disease | de Novo Coronary LesionsUnited States
-
Shenzhen People's HospitalNot yet recruitingde Novo Coronary Lesions
-
S.M. Misericordia HospitalCompletedStable Coronary Artery Disease | Silent Myocardial Ischemia | In-stent(BMS)Restenosis | De-novo, Atherosclerotic, Coronary LesionsItaly
-
Yinyi(Liaoning) Biotech Co., Ltd.CompletedCoronary Stenosis | De Novo Stenosis | Drug-coated Balloon | Coronary Artery Disease in Transplanted Heart AcceleratedChina
Clinical Trials on Stenting procedure
-
Scitech Produtos Medicos LtdaWithdrawnCardiovascular Diseases | Abdominal Aortic AneurysmBrazil
-
University of Roma La SapienzaCompleted
-
Centre Hospitalier Annecy GenevoisUniversity Hospital, GrenobleCompletedST Elevation Myocardial InfarctionFrance
-
Marco ValgimigliUnknownMyocardial InfarctionItaly
-
Catharina Ziekenhuis EindhovenTerminatedPeripheral Arterial Disease
-
Istanbul UniversityCompletedST-elevation Acute Myocardial InfarctionTurkey
-
Yonsei UniversityUnknownCholangiocarcinoma, Gallbladder Cancer, Pancreatic CancerKorea, Republic of
-
Istanbul Mehmet Akif Ersoy Educational and Training...Active, not recruitingCoronary Artery DiseaseTurkey
-
KCRISpectranetics CorporationTerminatedST Elevation Acute Myocardial InfarctionPoland
-
Fundacja Ośrodek Badań MedycznychTerminatedMyocardial Infarction | Coronary Artery DiseasePoland, Slovenia